Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Nutrients, Journal Year: 2024, Volume and Issue: 17(1), P. 143 - 143

Published: Dec. 31, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major contributor to liver-related morbidity, cardiovascular disease, and metabolic complications. Lifestyle interventions, including diet exercise, are first line in treating MASLD. Dietary approaches such as the low-glycemic-index Mediterranean diet, ketogenic intermittent fasting, high fiber diets have demonstrated potential addressing dysfunction underlying this condition. The development progression of MASLD closely associated with taxonomic shifts gut microbial communities, relationship well-documented literature. Given importance primary treatment for MASLD, it important understand how microbiota their byproducts mediate favorable outcomes induced by healthy dietary patterns. Conversely, changes conferred unhealthy patterns Western may induce dysbiosis influence through promoting hepatic inflammation, up-regulating lipogenesis, dysregulating bile acid metabolism, increasing insulin resistance, causing oxidative damage hepatocytes. Although emerging evidence has identified links between microbiota, significant gaps remain understanding specific roles, metabolite pathways, host interactions, causal relationships. Therefore, review aims provide mechanistic insights into role microbiota-mediated processes analysis both contribution pathophysiology. By better elucidating interplay nutrients, processes, onset work identify new opportunities targeted interventions treat efficiently.

Language: Английский

---

Gut microbiota differences, metabolite changes, and disease intervention during metabolic - dysfunction - related fatty liver progression

World Journal of Hepatology, Journal Year: 2025, Volume and Issue: 17(3)

Published: March 25, 2025

In the current era, metabolic dysfunction-associated steatotic liver disease (MASLD) has gradually developed into a major type of chronic that is widespread globally. Numerous studies have shown gut microbiota plays crucial and indispensable role in progression MASLD. Currently, become one important entry points for research this disease. Therefore, aim review to elaborate on further associations between MASLD, including changes differences healthy diseased liver. Meanwhile, considering fatty steatohepatitis are abnormal pathological states development exhibits different degrees fibrosis (such as mild severe fibrosis) during progression, we also conduct comparison these use them markers progression. It reveals production action mechanisms short-chain acids bile brought about by microbiota, impact lipopolysaccharide from Gram-negative bacteria addition, regulation inhibition related factors probiotics (including new-generation probiotics) will be explored, which help monitor patients with compositions future carry out personalized targeted therapies microbiota. This achieve progress preventing combating

Language: Английский

---

Gut microbiota in patients with metabolic, dysfunction-associated steatotic liver disease

Current Opinion in Clinical Nutrition & Metabolic Care, Journal Year: 2025, Volume and Issue: unknown

Published: April 24, 2025

Purpose of review Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent condition that can progress to fibrosis, steatohepatitis, and hepatocellular carcinoma. This examines recent advances concerning the role gut microbiota in MASLD microbiota-focused interventions positively impact outcome. Recent findings Dysbiotic compromised barrier facilitate translocation microbial-associated molecular patterns harmful metabolites into portal circulation liver, where they exacerbate inflammatory fibrogenic processes. Conversely, other bacterial have protective effects liver. Therefore, homeostasis essential for maintaining health. Summary Levels including ethanol, NH 3 , trimethylamine-L-oxide, 2-oleylglycerol, litocholic acid are often increased patients with MASLD. short-chain fatty acids, indole derivatives, histidine, acids taurodeoxycholic, 3-succinylcholic, hyodeoxycholic decreased. The main aim current interventions/treatments reduce increase beneficial ones. These include drugs (pemafibrate, metformin, obeticholic acid), natural compounds (silymarin, lupeol, dietary fiber, peptides), exogenous bacteria (probiotics, symbionts), special diets (Mediterranean diet, time-restricted feeding), as well transplantation, phage therapy. Most improve permeability, inflammation, fibrosis through regulation, promising alternatives MASLFD management. However, most results come from animal studies, while clinical trials lacking. Further research therefore needed this area.

Language: Английский

---

Unraveling MASLD: The Role of Gut Microbiota, Dietary Modulation, and AI-Driven Lifestyle Interventions

Nutrients, Journal Year: 2025, Volume and Issue: 17(9), P. 1580 - 1580

Published: May 4, 2025

Gut microbiota has a crucial role in the pathophysiology of metabolic-associated steatotic liver disease (MASLD), influencing various metabolic mechanisms and contributing to development disease. Dietary interventions targeting gut have shown potential modulating microbial composition mitigating MASLD progression. In this context, integration multi-omics analysis artificial intelligence (AI) personalized nutrition offers new opportunities for tailoring dietary strategies based on individual microbiome profiles responses. The use chatbots other AI-based health solutions unique opportunity democratize access due their low cost, accessibility, scalability. Future research should focus clinical validation AI-powered strategies, integrating microbiome-based therapies precision approaches. Establishing standardized protocols ethical guidelines will be implementing AI management, paving way more personalized, data-driven approach prevention treatment.

Language: Английский

---

Antibiotic-induced gut dysbiosis: unraveling the gut-heart axis and its impact on cardiovascular health

Molecular Biology Reports, Journal Year: 2025, Volume and Issue: 52(1)

Published: March 17, 2025

Language: Английский

---

Metabolic Characteristics and Cytokine Gene Polymorphisms as Potential Risk Factors for a Higher Liver Fibrosis Stage in MASLD Patients: A Hospital-Based Study

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(8), P. 3730 - 3730

Published: April 15, 2025

Polymorphisms in the Toll-like receptor 4 (TLR4) and IL-17 cytokine genes play a role liver fibrosis progression among patients with MASLD. The current study aimed to investigate whether IL17 (A7448G G197A) TLR4 (Asp299Gly Thr399Ile) gene polymorphisms are associated increased stages MASLD patients. Genotyping for IL17F-A7488G, IL17A-G197A, TLR4-Asp299Gly, TLR4-Thr399Ile was performed on sample of 42 39 healthy controls. Serum levels IL17F, IL17A, were measured using ELISA techniques. Bivariate analysis revealed significant associations between glycemic (p = 0.006), lipid metabolism (total cholesterol, HDL triglycerides), severity < 0.05). IL17A-G197A GA AA genotypes more frequent advanced compared those without (GA genotype frequency: 42.9% vs. 7.7%; 14.3% 5.1%; adjusted p 0.0423). In multivariable ordinal logistic regression, polymorphism remained significantly higher (adjusted 0.0155). Patients dominant + AA) exhibited 3.91 times greater odds experiencing at least one-stage increase GG OR 3.91, 95% CI: 1.33–12.34). This indicates that IL17-related genetic metabolic characteristics affect patients, identified as an independent multivariate predictor progression.

Language: Английский

---

Sex-Dependent Gut Microbiota Features and Functional Signatures in Metabolic Disfunction-Associated Steatotic Liver Disease

Nutrients, Journal Year: 2024, Volume and Issue: 16(23), P. 4198 - 4198

Published: Dec. 4, 2024

: This study investigates the gut microbiota's role in metabolic dysfunction-associated steatotic liver disease (MASLD), focusing on microbial and functional signatures sex-based differences.

Language: Английский

---

Valorizing Agro‐Food Waste for Nutraceutical Development: Sustainable Approaches for Managing Metabolic Dysfunction‐Associated Steatotic Liver Disease and Related Co‐Morbidities

Food Frontiers, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 25, 2024

ABSTRACT This comprehensive investigation delves into the interconnectedness of different features cardiometabolic syndrome, such as metabolic dysfunction‐associated steatotic liver disease (MASLD), atherosclerotic cardiovascular (ASCVD), and gut dysbiosis, highlighting crucial role nutraceuticals in their management prevention. Given significant overlap pathophysiology these conditions, treatment with nutraceuticals, especially those derived from agro‐food waste, offers a promising, sustainable, innovative approach to healthcare. The 2030 Agenda for Sustainable Development One Health concept are key frameworks selecting most interesting supply chain production ensuring environmental sustainability, agricultural practices. In this review, therapeutic potential kiwifruit apples has been explored, detailing how bioactive compounds, like polyphenols, fiber, pectin, kaempferol, phloretin, phlorizin, may contribute MASLD, ASCVD, dysbiosis. Various extraction methods active ingredients, including chemical, water, enzyme extractions, analyzed respective benefits drawbacks. By integrating scientific research, sustainable practices, methods, we can develop effective strategies combat pervasive health issues. holistic not only enhances individual outcomes but also supports broader societal goals, promoting healthier future all.

Language: Английский

---